{"id":493453,"date":"2026-06-19T00:00:00","date_gmt":"2026-06-19T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrmd0027-2025-biopharma-type-2-diabetes-current-treatment-current-treatment-physician-insights-glp-1-receptor-agonist\/"},"modified":"2026-07-13T23:12:16","modified_gmt":"2026-07-13T23:12:16","slug":"cutrmd0027-2026-biopharma-type-2-diabetes-current-treatment-current-treatment-physician-insights-glp-1-receptor-agonist","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrmd0027-2026-biopharma-type-2-diabetes-current-treatment-current-treatment-physician-insights-glp-1-receptor-agonist\/","title":{"rendered":"Type 2 Diabetes &#8211; Current Treatment &#8211; Current Treatment: Physician Insights &#8211; GLP-1 Receptor Agonist Products (US)"},"content":{"rendered":"<p>Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk\u2019s <abbr data-abbreviation-entity=\"4958\" title=\"subcutaneous\">SC<\/abbr> semaglutide (Ozempic \/ Wegovy) and Eli Lilly\u2019s tirzepatide (Mounjaro \/ Zepbound) have seen significant growth in recent years. Physicians and patients are increasingly drawn to these therapies for their proven clinical efficacy, convenient dosing, and overall safety profiles. Prescribing decisions for <abbr data-abbreviation-entity=\"5035\" title=\"glucagon-like peptide\">GLP<\/abbr>-1 <abbr data-abbreviation-entity=\"6530\" title=\"receptor agonist\">RA<\/abbr> products are shaped by multiple factors, including clinical trial outcomes, real-world evidence, and patient-specific considerations such as comorbidities. However, barriers such as cost and challenging reimbursement often limit broader adoption. Understanding what drives physician prescribing behavior is crucial for optimizing the use of <abbr data-abbreviation-entity=\"5035\" title=\"glucagon-like peptide\">GLP<\/abbr>-1 <abbr data-abbreviation-entity=\"6530\" title=\"receptor agonist\">RA<\/abbr> products and addressing gaps in patient care as demand for effective metabolic therapies continues to rise.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What is the perception of endocrinologists versus primary care physicians regarding the use of <abbr data-abbreviation-entity=\"5035\" title=\"glucagon-like peptide\">GLP<\/abbr>-1 <abbr data-abbreviation-entity=\"6530\" title=\"receptor agonist\">RA<\/abbr> products for the treatment of <abbr data-abbreviation-entity=\"5055\" title=\"type 2 diabetes\">T2D<\/abbr> and obesity?<\/li>\n<li>Which <abbr data-abbreviation-entity=\"5035\" title=\"glucagon-like peptide\">GLP<\/abbr>-1 <abbr data-abbreviation-entity=\"6530\" title=\"receptor agonist\">RA<\/abbr> products are most preferred vs. most prescribed among specialists for patients with <abbr data-abbreviation-entity=\"5055\" title=\"type 2 diabetes\">T2D<\/abbr> and\/or obesity?<\/li>\n<li>What impact would the removal of barriers to prescribing <abbr data-abbreviation-entity=\"5035\" title=\"glucagon-like peptide\">GLP<\/abbr>-1 <abbr data-abbreviation-entity=\"6530\" title=\"receptor agonist\">RA<\/abbr> products have on physicians\u2019 prescribing behavior for other approved drugs?<\/li>\n<li>What factors influence the prescription choices of endocrinologists when prescribing a <abbr data-abbreviation-entity=\"5035\" title=\"glucagon-like peptide\">GLP<\/abbr>-1 <abbr data-abbreviation-entity=\"6530\" title=\"receptor agonist\">RA<\/abbr> brand to <abbr data-abbreviation-entity=\"5055\" title=\"type 2 diabetes\">T2D<\/abbr> patients who are obese?<\/li>\n<\/ul>\n<p><b>Content highlights<\/b><\/p>\n<ul class=\"round-bullets\">\n<li>Geography: United States<\/li>\n<li>Primary research: survey of 100 U.S. endocrinologists and primary care physicians \/ general practitioners<\/li>\n<li>Key drugs covered: Ozempic, Rybelsus, Saxenda,\u00a0Trulicity, Wegovy, Zepbound<\/li>\n<li>Key insights provided:\n<ul class=\"round-bullets\">\n<li>Factors influencing disease management and treatment decisions<\/li>\n<li>Drivers and constraints of drug selection<\/li>\n<li><span>Physician-reported treatment practices<\/span><\/li>\n<li>Physician insight on compliance<\/li>\n<\/ul>\n<\/li>\n<li>Physician-reported recent \/ anticipated changes in drug usage or treatment approach<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<div>\n<p>Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:<\/p>\n<\/div>\n<div>\n<ul class=\"BulletListStyle1 SCXW32682493 BCX0 round-bullets\">\n<li>Understand the treatment landscape for a disease and how physicians make prescribing decisions.<\/li>\n<\/ul>\n<\/div>\n<div>\n<ul class=\"BulletListStyle1 SCXW32682493 BCX0 round-bullets\">\n<li>Evaluate the drivers and obstacles that influence treatment selection.<\/li>\n<\/ul>\n<\/div>\n<div>\n<ul class=\"BulletListStyle1 SCXW32682493 BCX0 round-bullets\">\n<li>Analyze your brand\u2019s performance from the physician perspective to enhance or defend your competitive position.<\/li>\n<\/ul>\n<\/div>\n","protected":false},"template":"","class_list":["post-493453","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-type-1-diabetes","biopharma-therapy-areas-type-2-diabetes","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/493453","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=493453"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}